Parkin Blocking Peptide (#BLP-NR103) is the original antigen used for immunization during Anti-Parkin Antibody (#ANR-103) generation. The blocking peptide binds and ‘blocks’ Anti-Parkin primary antibody, this makes it a good negative reagent control to help confirm antibody specificity in western blot and immunohistochemistry applications. This control is also often called a pre-adsorption control.
- Western blot analysis of rat brain synaptosome preparation (lanes 1 and 3) and mouse brain lysates (lanes 2 and 4):1-2. Anti-Parkin Antibody (#ANR-103), (1:200).
3-4. Anti-Parkin Antibody, preincubated with Parkin Blocking Peptide (BLP-NR103).
- Western blot analysis of human SH-SY5Y neuroblastoma cell line lysate:1. Anti-Parkin Antibody (#ANR-103), (1:200).
2. Anti-Parkin Antibody, preincubated with Parkin Blocking Peptide (BLP-NR103).
- Expression of Parkin in rat brain 4th ventricle.Immunohistochemical staining of perfusion-fixed frozen rat brain sections with Anti-Parkin Antibody (#ANR-103), (1:200), followed by goat Anti-rabbit-AlexaFluor-488. A. Parkin immunoreactivity (green) appears along the wall of the 4th cerebral ventricle (arrows). B. Pre-incubation of the antibody with Parkin Blocking Peptide (BLP-NR103), suppressed staining. Cell nuclei are stained with DAPI (blue). 4th V= 4th ventricle.
- Peptide (C)KELHHFRILGEEQYTR, corresponding to amino acid residues 298 - 313 of mouse Parkin (Accession Q9WVS6).